Holista Colltech Limited (ASX:HCT): Supplements Revenue and Collagen Plans Shape 2026 Operations

Aditi Sarkar

12 October 2026 05:44 PM AEDT

Holista Colltech Limited (ASX:HCT): Supplements Revenue and Collagen Plans Shape 2026 Operations

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

2026 half-year results reflect different trends across supplements, food ingredients and collagen.
Dietary supplements remained the company’s principal Revenue contributor.
Gross Margin improved during the six months ended 30 June 2026.
The group reported a net loss that included costs associated with a legal settlement.
Ovine collagen Manufacturing plans and agricultural product orders remain operational priorities.

Holista Colltech Limited (ASX:HCT) develops and markets health and wellness products spanning dietary supplements, food ingredients, ovine collagen and agricultural solutions. The company’s 2026 half-year accounts show growing supplement revenue alongside reduced activity in some smaller divisions, while management continues planning a proposed collagen manufacturing Facility in Western Australia.

Half-Year Revenue and Profitability

For the six months ended 30 June 2026, Holista Colltech (ASX:HCT) reported group revenue of $2.99 million, an increase of 3.6%. Gross Profit reached $1.33 million, while gross margin was 44.3%.

The group recorded a net loss after tax of $2.56 million. Its interim report attributed approximately $2.66 million to one-off costs associated with the ProImmune settlement and stated that profit after tax excluding those costs was approximately $0.095 million. This adjusted figure is a company-provided measure rather than the statutory net result.

Supplements Lead the Business Mix

The dietary supplements division generated revenue of $2.91 million in the first half of 2026, increasing 12.2%. Holista Colltech (ASX:HCT) cited an expanded marketplace presence, changes to its sales and Marketing activities, and resolution of a legacy returns matter among the relevant business developments.

The company also introduced a refreshed E-commerce website and expanded to TikTok Shop during the period. These steps concern its distribution strategy rather than clinical drug development.

Food Ingredients, Collagen and Agriculture

Food ingredients revenue was $29,963 during the half-year. The company linked reduced activity to inventory decisions by a major customer undergoing a privatisation process. Holista Colltech (ASX:HCT) continues to identify product innovation in the food ingredients division as a business priority.

Ovine collagen revenue was $28,781. The company reported progress on a proposed collagen manufacturing facility through its joint-venture arrangements, including completion of a land Acquisition in Collie, Western Australia. Planning and implementation remain ongoing; the land acquisition should not be interpreted as the start of commercial production.

The infection control and agriculture division recorded revenue of $23,484 from products including nano urea and poultry probiotics. Management described a transition from trial orders towards efforts to develop more recurring customer demand. Holista Colltech (ASX:HCT) has not established a quantified future revenue outcome for those activities in the figures discussed here.

Settlement and Financial Considerations

The company reported that its ProImmune dispute was settled for US$1.8 million, with final payment completed on 10 July 2026. Separately, it disclosed a July 2026 binding term sheet for an unsecured convertible Loan of $370,724, bearing 8% annual interest and subject to Shareholder approval for conversion into shares. The settlement costs materially affected the statutory half-year Earnings outcome.

For Holista Colltech (ASX:HCT), customer concentration within smaller divisions, operating expenditure, manufacturing implementation and Demand for consumer wellness products remain relevant business variables. Developments in those areas may influence reported performance without implying a particular future financial result.

Key Insights

Holista Colltech (ASX:HCT) entered the second half of 2026 with supplements contributing most reported revenue and gross margin higher than in the comparative reporting period. Its smaller operations remained at different stages of commercial activity, while the legal settlement significantly affected statutory earnings. Future company disclosures can clarify whether planned manufacturing and newer distribution channels translate into sustained operations.

FAQs

Q:What does Holista Colltech Limited do?

A:It operates in dietary supplements, healthy food ingredients, ovine collagen and agricultural solutions.

Q:What revenue did the company report for the first half of 2026?

A:Group revenue was $2.99 million for the six months ended 30 June 2026.

Q:Which division accounted for most reported revenue?

A:Dietary supplements, with $2.91 million in first-half 2026 sales.

Q:Why did the company report a net loss?

A:The $2.56 million loss included approximately $2.66 million in one-off settlement-related costs.

Q:What is the status of its Collie collagen facility?

A:The company reported a land acquisition for the proposed facility; planning and implementation were ongoing.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.